Skip to main content
. 2024 Jan 1;20(2):446–463. doi: 10.7150/ijbs.86085

Figure 6.

Figure 6

The VEGFA/NRP-1/GAPVD1 axis targeted the downstream Wnt/β-catenin signaling pathway. (A) Western blotting analysis of β-catenin and Wnt/β-catenin downstream targets in TNBC cells after treatment with 10 ng/ml hVEGF165. (B) Western blotting analysis of β-catenin and Wnt/β-catenin downstream targets in TNBC cells after VEGFA knockdown (shVEGFA). (C) Western blotting analysis of β-catenin and Wnt/β-catenin downstream targets in TNBC cells after NRP-1 knockdown (shNRP-1) in the presence or absence of 10 ng/ml hVEGF165. (D) Western blotting analysis of β-catenin and Wnt/β-catenin downstream targets in TNBC cells after GAPVD1 knockdown (shGAPVD1#2 and shGAPVD1#3). (E) Western blotting analysis of β-catenin and Wnt/β-catenin downstream targets in control and NRP-1-silencing TNBC cells after GAPVD1 overexpression (OE GAPVD1). The images show representative data, and data are expressed as the mean ± SD of each group of cells from three separate experiments. *P < 0.05, **P < 0.01, ****P < 0.0001 vs. the controls.